While ROS1+ NSCLC tumors were the dominant tumor type at 78.8% and has US FDA approved treatment of two ROS1 TKIs [8, 9], it implies that potentially more than 20% of the ROS1+ solid tumor may benefit from currently approved ROS1 TKIs. Here, ROS1 is linked to neoplasm.